Comparing two drug combos before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two treatments given before surgery for early-stage non-small cell lung cancer with high PD-L1. One group gets a new drug called cadonilimab, and the other gets a standard chemo plus an immunotherapy drug. The goal is to see which approach works better at shrinking tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer that can be removed with surgery (stage IB to IIIA).
- You have not received any prior treatment for this cancer.
- You are in generally good health, with a performance status of 0 or 1 (able to carry on daily activities).
- You have at least one measurable tumor and your lung function is good enough for surgery.
- You do not have cancer that has spread to other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests whether adding a bispecific antibody to chemotherapy before surgery helps treat advanced lung cancer better than a standard antibody. It is for people with stage II-III non-small cell lung cancer who have not had treatment yet.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.